Is there an oral PCSK9 inhibitor approved for clinical use?

Yes, Enlicitide is the First FDA-Approved Oral PCSK9 Inhibitor

As of July 2026, enlicitide became the first oral PCSK9 inhibitor approved by the FDA for treatment of hypercholesterolemia 1. This represents a major advancement over the previously available injectable PCSK9 inhibitors (evolocumab, alirocumab, and inclisiran).

Available Oral PCSK9 Inhibitors

Enlicitide (FDA-Approved)

• Approved July 2026 as a once-daily oral macrocyclic peptide 1
• Mechanism: Blocks the interaction between circulating PCSK9 and hepatic LDL receptors, increasing receptor recycling and LDL-C clearance 1
• Efficacy: Reduces LDL-C by approximately 60% at 24 weeks, with effects maintained through 52 weeks 2
• In the CORALreef Lipids trial (2,909 participants), enlicitide achieved a -57.1% LDL-C reduction versus +3.0% with placebo (adjusted difference -55.8 percentage points, P<0.001) 2
• Safety profile: Adverse event rates similar to placebo in phase III trials 1, 2

Laroprovstat (In Development)

• Not yet approved but shows promising phase 1 results 3
• Novel small-molecule that stabilizes the PCSK9 C-terminal domain, preventing lysosomal trafficking and LDL receptor degradation 3
• When combined with rosuvastatin 20 mg, laroprovstat 30 mg achieved approximately 80% total LDL-C reduction 3
• Well-tolerated with no safety concerns; can be dosed with or without food 3

Clinical Context and Guidelines

The existing guidelines 4, 5 were written before oral PCSK9 inhibitors became available and only address injectable formulations. However, the fundamental principles still apply:

When to Consider PCSK9 Inhibitors (Any Formulation)

• Very high cardiovascular risk patients already on maximally tolerated statin therapy with:
  • LDL-C ≥70 mg/dL (1.8 mmol/L) despite statin + ezetimibe 4
  • LDL-C ≥100 mg/dL (2.6 mmol/L) despite statin + ezetimibe (stronger indication) 4
• Statin-intolerant patients at very high or high cardiovascular risk 4
• Primary severe hypercholesterolemia or familial hypercholesterolemia with inadequate response to other therapies 4

Advantages of Oral Formulation

The oral route addresses key barriers that have limited injectable PCSK9 inhibitor uptake:

• Improved convenience and likely better long-term adherence 1
• Reduced injection-related concerns (injection site reactions occurred in <5% with injectable monoclonal antibodies) 5
• Greater accessibility and potentially reduced treatment inertia 1

Important Caveats

Lack of Cardiovascular Outcomes Data

The critical limitation is that enlicitide's approval was based on LDL-C reduction, not cardiovascular outcomes 1. The phase III trials (CORALreef Lipids and CORALreef HeFH) evaluated lipid parameters over 24-52 weeks but were not designed or powered to assess major adverse cardiovascular events 1, 2.

• The ongoing CORALreef Outcomes trial will determine whether enlicitide-mediated LDL-C reduction translates into fewer cardiovascular events 1
• Injectable PCSK9 inhibitors have proven cardiovascular benefit: 15% relative risk reduction in major cardiovascular events in FOURIER trial 5
• Meta-analysis of oral PCSK9 inhibitors shows comparable LDL-C lowering (-59.31%) to injectable agents 6, but cardiovascular outcomes remain unproven

Long-Term Safety Unknown

Current safety data extend only to 52 weeks 1, 2. Longer-term surveillance is needed to establish the safety profile comparable to injectable PCSK9 inhibitors, which have extensive post-marketing data.

Practical Recommendation

For patients requiring PCSK9 inhibition who prefer oral therapy or have barriers to injectable medications, enlicitide is now a viable option 1, 2. However, given the lack of cardiovascular outcomes data, injectable PCSK9 inhibitors (evolocumab, alirocumab) remain the evidence-based choice when cardiovascular event reduction is the primary goal, particularly in very high-risk patients with established atherosclerotic cardiovascular disease 4, 5.

The decision between oral and injectable PCSK9 inhibitors should weigh:

• Patient preference and likelihood of adherence
• Cardiovascular risk level (higher risk may favor proven injectable agents until outcomes data available)
• Cost and accessibility considerations
• Willingness to accept treatment based on surrogate endpoints versus hard cardiovascular outcomes